ImCheck Therapeutics receives EMA Orphan Drug Designation for ICT01 for treatment for acute myeloid leukemia: Marseille, France Thursday, July 24, 2025, 15:00 Hrs [IST] ImCheck Th ...

French biotech ImCheck Therapeutics has announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to its lead program, ICT01, a humanized anti-butyrophilin 3A (BTN3A ...

ImCheck Therapeutics’ contribution is a type of drug that could bring advantages over the first generation of cancer immunotherapies. Now the biotech has €96M that will help continue clinical ...

With all that on the to-do list, ImCheck Therapeutics has refueled with a 96 million euro ($101 million) funding round that featured existing investors Pfizer, Gimv and more.

ImCheck Therapeutics just raised $103 million to treat multiple forms of cancer. The company is working on one of the fastest-growing ideas in cancer research: gamma-delta T cells.

ImCheck to Present New Positive Data on ICT01 Monotherapyin Hematological Cancers at ESMO 2023Interim data from Phase I dose escalation portion of ...

The ASH poster will be available on ImCheck’s corporate website after the poster sessions have been opened. About the EVICTION Study EVICTION is a first-in-human, dose-escalation (Part 1) and ...

The ASCO presentation will be available on ImCheck’s corporate website after the presentation has been held. About the EVICTION Study EVICTION is a first-in-human, dose-escalation (Part 1) and ...

ImCheck Therapeutics raises €20 Million and appoints its CEO Emerging leader in immuno-oncology accelerates its development programs and prepares for entry into the clinic Marseille, France, May ...

ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer Marseille, France, November 5, 2024, 3 pm CET – ImCheck Therapeutics ...

Following the FDA ODD, European designation underscores ICT01’s potential as a ...

ImCheck’s ICT01 Receives FDA Orphan Drug Designation Clinical data showing unprecedented remission rates in newly diagnosed ...